Psychedelic-Assisted Therapy

What it is

Psychedelic-Assisted Therapy (PAT) refers to a set of emerging clinical protocols in which a psychoactive substance — most commonly ketamine, MDMA (3,4-methylenedioxymethamphetamine), or psilocybin — is used as a catalyst within a broader psychotherapeutic treatment. The substance is not the therapy on its own. Rather, it is understood to create a neurological and psychological state in which therapeutic work can proceed differently than it might in a standard talk therapy session: defenses may soften, emotional memories may become more accessible, and rigid patterns of thinking may temporarily loosen.

The theoretical roots of PAT reach back to psychiatric research conducted in the 1950s and 1960s, when several psychedelic compounds were studied for their potential in treating alcoholism, depression, and end-of-life distress. That research was halted by regulatory action in the late 1960s and early 1970s. The current clinical revival, which began gaining momentum in the early 2000s, has built new protocols that emphasize therapeutic structure, careful patient selection, and explicit integration work. Different substances produce meaningfully different experiences and carry different therapeutic hypotheses — MDMA research has focused heavily on PTSD, psilocybin on depression and existential distress, and ketamine on treatment-resistant depression — and these are not interchangeable approaches.

All legitimate PAT protocols share a three-phase structure: preparation (building therapeutic alliance and setting intentions before any substance is used), the dosing session itself (conducted in a supervised clinical setting), and integration (processing and making meaning of the experience in subsequent therapy sessions). The presence of all three phases is what distinguishes clinical PAT from any non-clinical use of these compounds.

What a session looks like

A PAT course typically begins with several preparation sessions that take place before any substance is introduced. In these meetings, you and your therapist or clinical team build a working relationship, discuss your history and treatment goals, and talk through what to expect. You will likely be given guidance on how to approach the dosing experience — including how to work with difficult emotions or imagery if they arise — and you may discuss intentions for the experience. This phase is not a formality; the quality of the therapeutic alliance formed here is considered to have a direct bearing on outcomes.

The dosing session itself takes place in a clinical setting designed to feel calm and contained rather than medical and sterile — many protocols use a comfortable reclining chair or bed, soft lighting, and a curated music playlist. Depending on the substance and protocol, the session may last between one hour (for some ketamine formats) and eight hours (for MDMA or psilocybin protocols). One or two therapists or guides are present throughout. You are typically encouraged to turn attention inward, often with eyeshades, and to allow the experience to unfold rather than directing it. Therapists do not usually lead active psychotherapy during the dosing window but remain present, offer reassurance, and may make brief verbal or physical contact (such as holding a hand) if distress arises.

After the dosing session, integration therapy begins — usually within 24 to 72 hours. These sessions involve talking through what arose during the dosing experience, identifying themes, and connecting insights to your daily life and treatment goals. Integration may continue for weeks or months. Many clinicians consider this phase the most clinically important, because the insights generated during a dosing session have limited value if they are not actively worked with afterward.

What it treats

PAT has been studied most extensively for post-traumatic stress disorder (PTSD), treatment-resistant depression, major depressive disorder, end-of-life anxiety and existential distress in people with serious illness, and alcohol use disorder. Within these areas, specific substances have accumulated more evidence than others: MDMA-assisted therapy has shown the most robust results for PTSD in Phase 3 clinical trials, psilocybin-assisted therapy has shown significant effect sizes for major depression and end-of-life distress, and ketamine has the most established clinical record for treatment-resistant depression, in part because it is the only compound that is currently widely legal for off-label clinical use in many countries.

PAT is not appropriate for everyone, and careful screening is a non-negotiable component of legitimate protocols. Contraindications vary by substance but generally include a personal or family history of schizophrenia, schizoaffective disorder, or psychosis; active manic or hypomanic episodes; uncontrolled cardiovascular conditions (particularly relevant to MDMA); and certain medication interactions (discussed further below). People with active suicidality, severe dissociative disorders, or borderline personality disorder in acute crisis require careful clinical evaluation before PAT would be considered, and some protocols exclude these presentations. Pregnancy is a contraindication for all PAT substances currently under study. PAT is not a first-line treatment for any condition and is typically considered after other approaches have been tried or in cases of significant treatment resistance.

What the evidence says

The evidence base for PAT has grown substantially since the early 2000s, with research published in peer-reviewed journals including high-impact general medical and psychiatry publications. Psilocybin-assisted therapy for depression has shown large effect sizes in randomized controlled trials (RCTs) conducted at institutions including Johns Hopkins University and Imperial College London, with some studies showing sustained benefit at weeks-long follow-up. MDMA-assisted therapy for PTSD completed Phase 3 RCTs through the Multidisciplinary Association for Psychedelic Studies (MAPS), with a significant proportion of participants no longer meeting PTSD diagnostic criteria after treatment — results that were considered clinically meaningful, though regulatory review has raised questions about blinding methodology and trial design that the field continues to address. Ketamine has an established evidence base for rapid-reduction of depressive symptoms, including suicidal ideation, and is the most regulated and accessible substance in the PAT category.

Important limitations apply across all PAT research. Blinding in psychedelic trials is inherently difficult — participants generally know whether they received an active substance or placebo — which introduces expectancy effects that are hard to fully account for. Sample sizes in most psilocybin and MDMA trials have been relatively small, and long-term follow-up data beyond several months remains limited. Replication across diverse populations, including people of color and those with complex comorbidities, is still underdeveloped. The field is also grappling with documented cases of ethical violations by practitioners, which have prompted renewed focus on training standards and safeguarding.

Field consensus is cautiously optimistic. Major psychiatric and psychological bodies have not yet issued endorsements of PAT as a standard-of-care treatment, reflecting both the regulatory status of most substances and the early stage of the evidence base. However, many professional organizations have acknowledged that the research warrants continued rigorous investigation, and several regulatory agencies have granted breakthrough therapy designations that expedite review. The science is serious; the work of establishing safety, efficacy, and equitable access is ongoing.

Who it is for

People who tend to be considered for PAT include those who have not found adequate relief through conventional treatments — for example, someone with PTSD who has completed evidence-based therapies such as EMDR or Prolonged Exposure without sufficient improvement, or someone with depression who has tried multiple antidepressant medications. Openness to a non-ordinary psychological experience is practically important: the dosing session can bring up vivid imagery, intense emotion, or unfamiliar states of consciousness, and people who are able to approach this with a degree of curiosity and tolerance for uncertainty tend to have more productive experiences. Stable housing, a supportive environment for recovery, and the capacity to engage in integration work are also factors clinicians consider.

Before beginning PAT, a thorough psychiatric and medical evaluation is essential. Anyone taking SSRIs (selective serotonin reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), lithium, antipsychotics, or benzodiazepines should discuss PAT with their prescribing clinician before proceeding, because interactions with these medications range from efficacy-reducing to potentially dangerous depending on the substance involved. Some protocols require a taper off certain medications before a dosing session, which must be medically supervised and should never be attempted without a prescriber's guidance. If you are working with a psychiatrist or GP who prescribes your psychiatric medications, that clinician should be part of the conversation before you begin PAT, not informed afterward.

How to find a practitioner

Verifying credentials in PAT requires more attention than for many other therapy modalities, because training standards vary widely and the field is not yet uniformly regulated. For ketamine, look for clinicians — typically physicians, nurse practitioners, or psychiatrists — who can speak specifically to their training in the psychotherapeutic component of the work, not only the pharmacological administration. A ketamine infusion administered without any psychotherapeutic framework is a different and more limited treatment than ketamine-assisted therapy conducted within a preparation-dosing-integration protocol. For psilocybin, legal facilitation is currently available in Oregon and Colorado in the United States under state-regulated frameworks, and practitioners in those contexts must hold a state-issued facilitator license. For MDMA, legal clinical access remains limited to active clinical trials in most jurisdictions. Before committing to any provider, ask directly: What specific training have you completed in psychedelic-assisted therapy, and with which organization? Have you received supervision in this modality, and do you continue to do so? What does your preparation and integration process look like, and how many sessions does it include? How do you handle a difficult or destabilizing experience during a session? What is your screening process, and what would lead you to recommend against proceeding?

Be cautious with vague claims. Phrases like 'holistic psychedelic healing' or 'consciousness expansion' without reference to specific clinical training or protocol structure are a signal to probe further. A qualified PAT provider will be able to name their training, describe their clinical protocol in concrete terms, and speak frankly about the risks and limitations of the approach. They should also ask you about your psychiatric and medical history in detail before agreeing to work with you — a provider who does not conduct thorough screening is a provider to be wary of.